new glp 1 agonist In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron GLP-1 Agonists For Obesity In
Description
However, as with injectable GLP-1s, cost may be a consideration in determining access to the Wegovy pill, particularly since many insurance plans dont cover obesity medications, Dushay says
GLP-1RAs have been shown to reduce the levels of systemic inflammatory markers
Gastrointestinal side effects remain among the most frequently cited challenges associated with currently marketed GLP-1 therapies and represent a significant driver of discontinuation
Time above the therapeutic INR range increased significantly after GLP-1 RA initiation, while time below range showed a numerical increase
